Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-07-28FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for divalproex sodium submitted by BluePoint Laboratories, associated with an existing ANDA.
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population [Phase 4]
A Phase 4 trial evaluated the efficacy and safety of add-on Alpha-lipoic Acid for migraine prophylaxis in adolescents and has completed.
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine [Phase 3]
A Phase 3 randomized, double-blind, placebo-controlled trial evaluating STS101 for acute treatment of migraine, with completed status and re…
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents [Phase 3]
Phase 3 study evaluating ONZETRA Xsail for acute treatment of episodic migraine in adolescents was terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-18Clinical Trial Update: Treatment for Migraine and Mood (Team-M) [Phase 2]
A Phase 2 clinical trial update for a treatment targeting migraine and mood disorders has completed and posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-07-17FDA Approved: TOPIRAMATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for Topiramate (generic).
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine [Phase 3]
A Phase 3 trial evaluating the safety of STS101 for acute treatment of migraine, completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine [Phase 3]
A Phase 3 randomized, double-blind, placebo-controlled trial evaluating STS101 for acute treatment of migraine has completed and posted resu…
-
FDA approval · 2023-06-22FDA Approved: DIHYDROERGOTAMINE MESYLATE — Original Application (Advagen Pharma Ltd)
FDA approved an original application for dihydroergotamine mesylate from Advagen Pharma Ltd, establishing this product as a new approved opt…
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Treatment of Insomnia in Migraineurs [Phase 4]
Phase 4 clinical trial update on treating insomnia in patients with migraine completed.
-
FDA approval · 2023-06-07FDA Approved: RIZATRIPTAN — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for rizatriptan submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2023-06-07FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for rizatriptan benzoate submitted by Macleods Pharmaceuticals Limited. It concerns a supplement…
-
FDA approval · 2023-06-06FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for sumatriptan succinate submitted by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants [Phase 3]
A Phase 3 clinical trial evaluating oral ubrogepant for acute treatment of migraine during the prodrome phase in adults has completed and re…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine [Phase 3]
A Phase 3 clinical trial update evaluating adverse events of oral atogepant in adult Chinese participants who completed a prior study, in or…
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. [Phase 3]
Phase 3 trial comparing valproate to memantine for the prophylaxis of episodic migraine has completed and posted results.
-
FDA approval · 2023-05-15FDA Approved: EXCEDRIN MIGRAINE GELTABS — Supplemental Application (Haleon US Holdings LLC)
The FDA approved a supplemental application for Excedrin Migraine Geltabs, adding a gelatin-based tablet form of the product that contains a…
-
FDA approval · 2023-05-04FDA Approved: TOPIRAMATE — Original Application (Endo USA, Inc.)
FDA approves Endo USA, Inc.'s original application for a generic Topiramate. Topiramate is used for epilepsy and migraine prophylaxis.
-
FDA approval · 2023-05-03FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved Janssen's supplemental application for Topamax (topiramate) and updated the product labeling.
-
FDA approval · 2023-04-17FDA Approved: EXCEDRIN MIGRAINE GELTABS — Supplemental Application (Haleon US Holdings LLC)
FDA approved a supplemental application for Excedrin Migraine GelTabs (acetaminophen, aspirin, caffeine) from Haleon US Holdings LLC.
-
FDA approval · 2023-04-17FDA Approved: QULIPTA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for QULIPTA (atogepant) from AbbVie Inc., expanding the product's approved indications.
-
FDA approval · 2023-04-04FDA Approved: PROCHLORPERAZINE MALEATE — Original Application (Bionpharma Inc.)
FDA approved an Original Application for Prochlorperazine Maleate from Bionpharma Inc., authorizing its marketing as a generic antiemetic.
-
FDA approval · 2023-03-31FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic sumatriptan succinate product from Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine [Phase 2, Phase 3]
A long-term safety study of BHV-3500 (zavegepant) for acute treatment of migraine has completed Phase 2/Phase 3 trials with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: Randomized Trial in Adult Participants With Acute Migraines [Phase 3]
Phase 3 randomized trial in adults with acute migraines completed; results posted in 2023.